Ignite Creation Date:
2025-12-24 @ 7:48 PM
Ignite Modification Date:
2025-12-28 @ 1:05 PM
Study NCT ID:
NCT00086203
Status:
COMPLETED
Last Update Posted:
2015-03-25
First Post:
2004-06-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
Sponsor:
Point Therapeutics
Organization:
Organization Data
Organization:
Class:
FED
Study ID:
PTH-203
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None